Abigail J. Porzucek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abigail J. Porzucek has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Nathan D. Grubaugh
Yale School of Public Health 4 Department of Epidemiology of Microbial Diseases New Haven, CT
2 shared publications Ana B. de Oliveira
Faculdade de Medicina de São José do Rio Preto 6 Laboratório de Pesquisas em Virologia, Departamento de Doenças dermatológicas, Infecciosas e Parasitárias São José do Rio Preto
1 shared publication- Carolina Lucas
Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
1 shared publication - Colin J. Carlson
Center for Global Health Science and Security, Georgetown University, Washington, USA
1 shared publication Daniel M. Weinberger
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA
1 shared publication- Daniela Weiskopf
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA
1 shared publication
Latest Publications
- 2 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4–targeted boosters.
- 2 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4–targeted boosters.
- Open Access
Standardizing annual dengue intensity reveals global drivers of transmission
Dengue incidence is increasing due to climate change and globalization, as well as enhanced case ascertainment. Despite the increasing transmission intensity of dengue virus, there is no standardized measure of disease burden, nor a standardized outbreak definition. Without such measures, it is difficult to understand how transmission patterns are changing over time and to identify what drives these changes globally. To address these problems, we developed a globally standardized metric of dengue burden, which we refer to as the Relative Intensity Score (RISc). RISc is an annual, country-level metric that measures short-term aberrations in dengue incidence relative to location- and time-specific baselines. We derived RISc estimates for 57 countries from 1990-2023 and then used RISc to identify years in which each country experienced outbreak-level transmission. Using these measures, we then examined patterns of RISc over time and found that years with increased RISc tend to cluster together, suggesting that changes in intensity are sustained through multi-year cycles. Finally, we identified factors associated with increased RISc on global and regional scales and found that increases in temperature were associated with the greatest increases in intensity. In sum, this study provides a globally standardized measure of dengue burden and demonstrates how this metric can be utilized to uniformly identify outbreak occurrence, track changing epidemiologic patterns, and identify environmental factors driving changes in intensity.
Open AccessStandardizing annual dengue intensity reveals global drivers of transmission
Dengue incidence is increasing due to climate change and globalization, as well as enhanced case ascertainment. Despite the increasing transmission intensity of dengue virus, there is no standardized measure of disease burden, nor a standardized outbreak definition. Without such measures, it is difficult to understand how transmission patterns are changing over time and to identify what drives these changes globally. To address these problems, we developed a globally standardized metric of dengue burden, which we refer to as the Relative Intensity Score (RISc). RISc is an annual, country-level metric that measures short-term aberrations in dengue incidence relative to location- and time-specific baselines. We derived RISc estimates for 57 countries from 1990-2023 and then used RISc to identify years in which each country experienced outbreak-level transmission. Using these measures, we then examined patterns of RISc over time and found that years with increased RISc tend to cluster together, suggesting that changes in intensity are sustained through multi-year cycles. Finally, we identified factors associated with increased RISc on global and regional scales and found that increases in temperature were associated with the greatest increases in intensity. In sum, this study provides a globally standardized measure of dengue burden and demonstrates how this metric can be utilized to uniformly identify outbreak occurrence, track changing epidemiologic patterns, and identify environmental factors driving changes in intensity.